BRENTUXIMAB-VEDOTIN AND BENDAMUSTINE IS A FEASIBLE AND EFFECTIVE DRUG COMBINATION AS FIRST-LINE TREATMENT OF HODGKIN LYMPHOMA IN THE ELDERLY (HALO TRIAL)

Authors :: C. Patti
Roberto Sorasio
C. Debaigt
Fontanet Bijou
E. Chamorey
Antoine Thyss
S. Viviani
Andrea Gallamini
Antonella Russo Rossi
J. Viotti
A. Perrot
Lauris Gastaud
Source :: Hematological Oncology. 35:170-170
Publication Year :: 2017
Publisher :: Wiley, 2017.

Subjects :: Drug
Oncology
Bendamustine
Cancer Research
medicine.medical_specialty
business.industry
media_common.quotation_subject
Hematology
General Medicine
First line treatment
Internal medicine
medicine
Hodgkin lymphoma
Halo
Brentuximab vedotin
business
media_common
medicine.drug

Full Text Access

Tools